No connection

Search Results

SERA

BEARISH
$2.3 Live
Sera Prognostics, Inc. · NASDAQ
Target $5.0 (+117.4%)
$1.37 52W Range $4.09
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 19, 2026
Market cap
$90.03M
P/E
N/A
ROE
-51.8%
Profit margin
N/A
Debt/Equity
0.03
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
SERA presents a contradictory profile with a stable Piotroski F-Score of 6/9 but catastrophic operational metrics. While the balance sheet remains lean with very low debt (D/E 0.03) and adequate liquidity, the company is experiencing a severe revenue collapse (-58.3% YoY) and negative gross margins (-102.47%), indicating that the cost of producing its services exceeds the revenue generated. The extreme Price-to-Sales ratio (1111.49) and aggressive insider selling suggest a lack of confidence in the current business model, rendering the single analyst's 'strong buy' rating highly speculative.

Key Strengths

Low leverage with a Debt/Equity ratio of 0.03
Stable short-term liquidity (Current Ratio 1.69)
Piotroski F-Score of 6/9 indicates stable financial health relative to its own history
Recent trend of beating EPS estimates (3 of last 4 quarters)
Low Price-to-Book ratio (1.19) suggesting the stock is trading near its accounting value

Key Risks

Severe revenue contraction (-58.3% YoY and Q/Q)
Negative gross margins (-102.47%) indicating a non-viable cost structure
Extreme valuation relative to sales (P/S 1111.49)
Strong insider selling pressure with 15 sell transactions and 0 buys
Long-term price erosion with an 80.7% decline over 5 years
AI Fair Value Estimate
Based on comprehensive analysis
$1.93
-16.1% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
22
Weak
Value
15
Future
10
Past
20
Health
65
Dividend
0
AI Verdict
High Risk / Speculative
Key drivers: Revenue collapse, Negative gross margins, Insider divestment, Low debt cushion
Confidence
90%
Value
15/100

Ref P/E, PEG, Graham Number

Positives
  • P/B ratio is relatively low at 1.19
Watchpoints
  • P/S ratio of 1111.49 is fundamentally unjustifiable
  • No Graham Number available due to lack of earnings
Future
10/100

Ref Growth rates

Positives
  • Recent EPS beats
Watchpoints
  • Revenue growth is deeply negative (-58.3%)
  • Operating margins are profoundly negative
Past
20/100

Ref Historical trends

Positives
  • Short-term 1-month price recovery (+20.4%)
Watchpoints
  • 5-year return of -80.7%
  • Consistent failure to achieve profitability
Health
65/100

Ref Altman Z-Score, Piotroski F-Score

Positives
  • Piotroski F-Score 6/9
  • Very low Debt/Equity (0.03)
  • Current Ratio 1.69
Watchpoints
  • Negative ROE and ROA
Dividend
0/100

Ref Yield, Payout

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • No history of payouts

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$2.3
Analyst Target
$5.0
Upside/Downside
+117.4%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for SERA and closest competitors.

Updated 2026-04-17
SER
Sera Prognostics, Inc.
Primary
5Y
-80.7%
3Y
-29.7%
1Y
-32.4%
6M
-28.1%
1M
+20.4%
1W
+16.8%
GOS
Gossamer Bio, Inc.
Peer
5Y
-95.6%
3Y
-66.2%
1Y
-57.8%
6M
-85.5%
1M
-26.7%
1W
+0.4%
OKY
OKYO Pharma Limited
Peer
5Y
-54.4%
3Y
+32.0%
1Y
+47.3%
6M
-20.3%
1M
-1.8%
1W
+3.8%
BDS
Biodesix, Inc.
Peer
5Y
-97.8%
3Y
-75.2%
1Y
-34.9%
6M
+31.6%
1M
+72.1%
1W
+49.0%
MXC
MaxCyte, Inc.
Peer
5Y
-94.8%
3Y
-83.5%
1Y
-66.1%
6M
-46.6%
1M
+8.7%
1W
+24.1%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-3.36
PEG Ratio
N/A
P/B Ratio
1.19
P/S Ratio
1111.49
EV/Revenue
656.41
EV/EBITDA
-1.49
Market Cap
$90.03M

Profitability

Profit margins and return metrics

Profit Margin N/A
Operating Margin -89540.0%
Gross Margin -102.47%
ROE -51.83%
ROA -26.15%

Growth

Revenue and earnings growth rates

Revenue Growth -58.3%
Earnings Growth N/A
Q/Q Revenue Growth -58.33%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.03
Low debt
Current Ratio
1.69
Good
Quick Ratio
1.62
Excellent
Cash/Share
$1.0

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
-320.0%
Op. Margin
-89540.0%
Net Margin
-78810.0%
Total Assets
$0.1B
Liabilities
$0.0B
Equity
$0.1B
Debt/Equity
0.35x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
105%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-06
$N/A
2026-03-18
$-0.16
+15.8% surprise
2025-11-13
$-0.16
+23.8% surprise
2025-08-06
$-0.16
+33.3% surprise

Healthcare Sector Comparison

Comparing SERA against 447 companies in the Healthcare sector (26 bullish, 140 neutral, 281 bearish)
Return on Equity (ROE)
-51.83%
This Stock
vs
-97.42%
Sector Avg
-46.8% (Below Avg)
Debt to Equity
0.03
This Stock
vs
3.06
Sector Avg
-99.0% (Less Debt)
Revenue Growth
-58.3%
This Stock
vs
147.85%
Sector Avg
-139.4% (Slower)
Current Ratio
1.69
This Stock
vs
4.68
Sector Avg
-63.9% (Weaker)

Similar Companies

Peer comparison within the same industry

SERA Sera Prognostics, Inc.
BEARISH
Mkt Cap
$90M
P/E
-
ROE
-51.8%
Price
$2.3
GOSS Gossamer Bio, Inc.
BEARISH
Mkt Cap
$87M
P/E
-
ROE
-%
Price
$0.37
 Compare with SERA
OKYO OKYO Pharma Limited
BEARISH
Mkt Cap
$87M
P/E
-
ROE
-%
Price
$1.65
 Compare with SERA
BDSX Biodesix, Inc.
BEARISH
Mkt Cap
$94M
P/E
-
ROE
-302.6%
Price
$11.74
 Compare with SERA
MXCT MaxCyte, Inc.
BEARISH
Mkt Cap
$94M
P/E
-
ROE
-23.6%
Price
$0.88
 Compare with SERA

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

LINDGARDT ZHENYA
Chief Executive Officer
Stock Award
2026-03-12
154,440 shares
AERTS AUSTIN
Chief Financial Officer
Stock Award
2026-03-12
44,215 shares
ANDERSON DYAARL LEE JR
Officer
Stock Award
2026-03-12
12,455 shares
INGLIS TIFFANY EUL DAVIS
Officer
Stock Award
2026-03-12
17,437 shares
JACKSON BENJAMIN R
General Counsel
Stock Award
2026-03-12
44,215 shares
KEARNEY PAUL
Officer
Sell
2026-03-11
1,396 shares · $2,848
LINDGARDT ZHENYA
Chief Executive Officer
Sell
2026-03-11
25,612 shares · $49,079
AERTS AUSTIN
Chief Financial Officer
Sell
2026-03-11
7,088 shares · $13,610
HARRISON ROBERT GARDNER
Chief Technology Officer
Sell
2026-03-11
716 shares · $1,461
JACKSON BENJAMIN R
General Counsel
Sell
2026-03-11
1,027 shares · $2,095
BONIFACE JOHN J
Officer
Sell
2026-03-11
1,517 shares · $3,095
KEARNEY PAUL
Officer
Sell
2026-03-09
2,026 shares · $3,971
AERTS AUSTIN
Chief Financial Officer
Sell
2026-03-09
674 shares · $1,321
HARRISON ROBERT GARDNER
Chief Technology Officer
Sell
2026-03-09
3,360 shares · $6,586
JACKSON BENJAMIN R
General Counsel
Sell
2026-03-09
3,119 shares · $6,113
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
8-K
2026-03-18
10-K
10-K
2026-03-18

SERA filed its annual 10-K report on March 18, 2026. The provided excerpts do not contain specific financial highlights or detailed risk factors.

8-K
8-K
2026-01-08
8-K
8-K
2026-01-07
8-K
8-K
2025-11-24
10-Q
10-Q
2025-11-13

SERA filed its 10-Q on November 13, 2025, which includes a section on Risk Factors under Item 1A. No specific financial highlights or detailed risk descriptions were provided in the available excerpts.

8-K
8-K
2025-11-13
8-K
8-K
2025-09-05
10-Q
10-Q
2025-08-06

SERA filed its quarterly 10-Q report on August 6, 2025. While specific financial metrics were not provided in the excerpt, the filing includes a detailed section on Risk Factors under Item 1A.

8-K
8-K
2025-08-06

Sera Prognostics Corporation filed a current report on August 6, 2025, likely announcing its second-quarter financial results.

8-K
8-K
2025-06-05
8-K
8-K
2025-05-08
10-Q
10-Q
2025-05-07
8-K
8-K
2025-05-07
DEF 14A
DEF 14A
2025-04-23
Data sourced from SEC EDGAR. AI summaries generated automatically.

Past News Coverage

Recent headlines mentioning SERA from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile